ACC: Improved Outcomes in Interventional Cardiology, EP

 
April 5, 2007

The AXIOM Sensis XP combines both hemo and advanced EP applications in one system. The system delivers clinical workflow support programs that are flexible and customizable. Reports are generated automatically, based on customizable templates, integrating database entries and key images. High signal quality means diagnostic confidence during procedures.

More like this

The content of this field is kept private and will not be shown publicly.
By submitting this form, you accept the Mollom privacy policy.

Related News

Dual Chamber Defibrillators Pose Higher Risk of Complications

May 20, 2013 — A device commonly used to treat dangerous heart rhythms may cause more issues for patients than a simpler version of the same device. The...

Multiple Studies Show Promise for Innovative FIRM Rotor Mapping Method

May 16, 2013 — New research presented at Heart Rhythm 2013 continues to show promising results for focal impulse and rotor modulation (FIRM) mapping to effectively target atrial fibrillation (AF)...

Nearly 50 Percent of Patients With Cardiac Device Infections Don’t Survive Beyond Three Years

May 16, 2013 — The incremental mortality in implantable pacemaker and defibrillator recipients who experience a device infection, compared to patients without device infection, is substantial and...

View all

Related Articles

Multiple Studies Show Promise for Innovative FIRM Rotor Mapping Method

May 16, 2013 — New research presented at Heart Rhythm 2013 continues to show promising results for focal impulse and rotor modulation (FIRM) mapping to effectively target atrial fibrillation (AF)...

Nearly 50 Percent of Patients With Cardiac Device Infections Don’t Survive Beyond Three Years

May 16, 2013 — The incremental mortality in implantable pacemaker and defibrillator recipients who experience a device infection, compared to patients without device infection, is substantial and...

Study Compares Multidisciplinary Convergent Procedure to Endocardial Catheter Ablation to Treat AF

May 14, 2013 — nContact Inc. said it received conditional approval for an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin enrollment in...

View all